Vertex Pharmaceuticals Incorporated

Vertex's vanzacaftor/tezacaftor/deutivacaftor triple therapy NDA accepted by FDA for cystic fibrosis, targeting those aged 6+ with at least one F508del or responsive mutation in CFTR gene. PDUFA action date set for January 2, 2025, with EMA validation also received.